newsfilter
← Latest News
PR Newswire·

DURECT Corporation to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide a Business Update

DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated ...